Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001241614 | SCV001414642 | uncertain significance | Glycogen storage disease, type V | 2019-04-29 | criteria provided, single submitter | clinical testing | This sequence change replaces aspartic acid with histidine at codon 328 of the PYGM protein (p.Asp328His). The aspartic acid residue is moderately conserved and there is a moderate physicochemical difference between aspartic acid and histidine. This variant is present in population databases (rs758682386, ExAC 0.05%). This variant has not been reported in the literature in individuals with PYGM-related disease. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Not Available"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Not Available"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Revvity Omics, |
RCV001241614 | SCV003818085 | uncertain significance | Glycogen storage disease, type V | 2019-04-05 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003166506 | SCV003911234 | uncertain significance | Inborn genetic diseases | 2023-03-13 | criteria provided, single submitter | clinical testing | The c.982G>C (p.D328H) alteration is located in exon 8 (coding exon 8) of the PYGM gene. This alteration results from a G to C substitution at nucleotide position 982, causing the aspartic acid (D) at amino acid position 328 to be replaced by a histidine (H). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Mayo Clinic Laboratories, |
RCV004793340 | SCV005412360 | uncertain significance | not provided | 2024-06-06 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001241614 | SCV002092331 | uncertain significance | Glycogen storage disease, type V | 2020-03-10 | no assertion criteria provided | clinical testing |